Immunome Entered Amendment No. 4 To License Agreement With Bristol-Myers Squibb On October 2, 2026

Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA

Dollar General, Bristol-Myers Squibb, and Equinor ASA have received broker rating upgrades despite macroeconomic headwinds. All three stocks show positive earnings growth expectations and improved analyst sentiment, with Equinor showing the strongest projected earnings growth at 120.7% year-over-year.

Bristol-Myers Squibb shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $73 to $59.

Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

8-K filing — Immunome Inc. (IMNM)

Filed: 2026-10-05 AccNo: 0001193125-26-413217 Size: 329 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24

Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors